Vitamin D supplementation dose needs to be higher in patients with inflammatory bowel disease: interventional study

Česká verzia

Authors: Vladimír Kojecký ¹; Jan Matouš ²; Zdena Zádorová ³; Martin Gřiva ¹; Bohuslav Kianička ³; Michal Uher ⁴
Authors place of work: Interní klinika Krajské nemocnice T. Bati ve Zlíně ¹; II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha ²; II. interní klinika LF MU a FN U sv. Anny v Brně ³; Institut biostatistiky a analýz MU, Brno ⁴
Published in the journal: Vnitř Lék 2019; 65(7-8): 470-474
Category: Original Contributions

Summary

Introduction: Vitamin D (vitD) is a substance with an immunomodulatory effect. Its insufficiency has negative impact also on inflammatory bowel disease (IBD) where it is often present. The recommended daily intake for general population is 600 UI/day (units/day). What is the necessary dose for IBD patients remains unknown. The aim of the study was to verify whether the 2,000 IU/day of vitD is sufficient for maintaining sustained levels in these patients.

Methods: Patients with Crohn’s disease (CD) or ulcerative colitis (UC) were supplemented orally with 2,000 IU of cholecalciferol daily during winter time. The level of 25-hydroxyvitamin D (25OHD) was established at the beginning of substitution period (October to December) and in Month 4. Demographic data, Ca, P, parathormone levels, dose of vitD used, and patient’s compliance were observed.

Results: 108 patients with CD and UC (71/37) were analysed, out of them 51 females, average age 43.3 ± 16.2 years. The level of 25OHD increased from 60.2 ± 26.5 nmol/l to 68.1 ± 27.1 nmol/l (p < 0.001) during the period with the average substitution dose of vitD 1 858 ± 464 IU/day. 60.2 % of subjects complied with the recommended dosing of vitD. The dose of 1,820 IU vitD/day showed to be sufficient for maintaining sustained levels in the model. No changes of Ca, P serum levels occurred during observation period.

Conclusions: Substitution doses of vitD recommended for general population are insufficient for IBD patients. A dose of up to 2,000/day, which is safe, is necessary to maintain normal levels of 25OHD. Noncompliance with the use of vitD is high.

Keywords:

supplementation – Ulcerative colitis

Zdroje

Reich KM, Fedorak RN, Madsen K et al. Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World J Gastroenterol 2014; 20(17): 4934–4947. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v20.i17.4934>.
Ashwin N, Ananthakrishnan AN, Cagan A et al. Normalization of Plasma 25-hydroxy Vitamin D is Associated with Reduced Risk of Surgery in Crohn’s Disease. Inflamm Bowel Dis 2013; 19(9): 1921–1927. Dostupné z DOI: <http://dx.doi.org/10.1097/MIB.0b013e3182902ad9>.
Miznerova E, Hlavaty T, Koller T et al. The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease. Bratisl Lek Listy 2013; 114(8): 439–445.
[EFSA panel on dietetic products, nutrition and allergies (NDA)]. Scientific Opinion on the Tolerable Upper Intake Level of vitamin D. EFSA Journal 2012; 10(7): 2813. Dostupné z DOI: <http://dx.doi.org/10.2903/j.efsa.2012.2813>.
Kojecky V, Matous J, Zadorova Z et al. Vitamin D substitution dose in IBD patients: Higher than recommended? J Crohns Colitis 2018; 12(Suppl 1): S401.
Freeeman J, Wilson K, Spears E et al. Performance evaluation of four 25-hydroxyvitamin D assays to measure 25-hydroxyvitamin D2. Clin Biochem 2015; 48(16–17):1097–1104. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clinbiochem.2015.05.021>.
Gose M, Krems C, Heuer T et al. Trends in food consumption and nutrient intake in Germany between 2006 and 2012: results of the German National Nutrition Monitoring (NEMONIT). Br J Nutr 2016; 115(8): 1498–5077. Dostupné z DOI: <http://dx.doi.org/10.1017/S0007114516000544>.
Blahoš J, Vyskočil V. Kalcium, vitamin D a zdraví. Vnitř Lék 2014; 60(9): 691–695.
9.Ross AC, Taylor CL, Yaktine AL et al. [Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium]. Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press (US): Washington (DC) 2011. ISBN 978–0-309–16394–1. Dostupné z WWW: <http://www.ncbi.nlm.nih.gov/books/NBK56070/>.
Magro F, Gionchetti P, Eliakim R et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2011; 11(6): 649–670. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjx008>.
Singh G, Bonham AJ. A predictive equation to guide vitamin D replacement dose in patients. J Am Board Fam Med 2014; 27(4): 495–509. Dostupné z DOI: <http://dx.doi.org/10.3122/jabfm.2014.04.130306>.
Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911–1930. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–0385>. Erratum in J Clin Endocrinol Metab 2011; 96(12): 3908.
Hlavaty T, Krajcovicova A, Koller T et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J Gastroenterol 2014; 20(42): 15787–15796. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v20.i42.15787>.
Leichtmann GA, Bengoa JM, Bolt MJ et al. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn‘s disease and intestinal resection. Am J Clin Nutr 1991; 54(3): 548–552. Dostupné z DOI: <http://dx.doi.org/10.1093/ajcn/54.3.548>.
Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn‘s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105(1): 162–169. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2009.545>.
Mazahery H, von Hurst PR. Factors Affecting 25-Hydroxyvitamin D Concentration in Response to Vitamin D Supplementation. Nutrients 2015; 7(7): 5111–5142. Dostupné z DOI: <http://dx.doi.org/10.3390/nu7075111>.
Raftery T, O‘Sullivan M. Optimal vitamin D levels in Crohn‘s disease: a review. Proc Nutr Soc 2015; 74(1): 56–66. Dostupné z DOI: <http://dx.doi.org/10.1017/S0029665114001591>.
Ish-Shalom S, Segal E, Salganik T et al. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 2008; 93(9): 3430–3435. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008–0241>.